Form 4: CRISPR Therapeutics Director John Greene Reports Share Purchase and Sale
SEC Form 4 Filing
Director John Greene of CRISPR Therapeutics AG reports purchasing and disposing of common shares on February 26, 2025.
Summary
- On February 26, 2025, John Greene, a director of CRISPR Therapeutics AG, engaged in transactions involving the company's common shares.
- Greene purchased 7,000 common shares at a weighted average price of $44.8497.
- Greene disposed of 7,000 common shares at prices ranging from $44.84 to $44.85.
- The transactions were executed in the open market and aligned with the issuer's trading policies.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like directors, who trade in their company's stock. It provides transparency to the market regarding the trading activities of those with privileged information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by providing insight into the director's trading activity.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date of the reported transaction involving the purchase and sale of common shares. |
| 02/28/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.